As per the agreement, OctoPlus is expected to develop, making use of its PolyActive technology, in-vivo feasibility, a controlled release formulation of an undisclosed compound. Novartis is expected to fully reimburse OctoPlus for its activities under the agreement.
OctoPlus claimed that its biodegradability, safety record and linear release properties make PolyActive an appropriate technology for the controlled release of proteins and lipophilic small molecules.
OctoPlus added that products based on PolyActive can be used for both local and systemic administration, and have applications in pharmaceutics and medical technology.
Simon Sturge, CEO of OctoPlus, said: “This along with the recent data on Locteron in more than 175 patients continues to build the support behind our PolyActive controlled release technology.”